{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tumor+Necrosis+Factor+Inhibitors&page=3", "query": { "intervention": "Tumor Necrosis Factor Inhibitors", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 72, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tumor+Necrosis+Factor+Inhibitors&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tumor+Necrosis+Factor+Inhibitors&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T19:41:33.215Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04086745", "title": "A Study of Baricitinib in Participants With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "TNF Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1050, "start_date": "2020-02-14", "completion_date": "2025-05-19", "has_results": true, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-11T19:41:33.215Z", "location_count": 119, "location_summary": "Chandler, Arizona • Mesa, Arizona • Paradise Valley, Arizona + 104 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04086745" }, { "nct_id": "NCT01768572", "title": "To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "sarilumab SAR153191 (REGN88)", "type": "DRUG" }, { "name": "tocilizumab", "type": "DRUG" }, { "name": "hydroxychloroquine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "sulfasalazine", "type": "DRUG" }, { "name": "leflunomide", "type": "DRUG" }, { "name": "subcutaneous placebo", "type": "DRUG" }, { "name": "intravenous placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2013-03", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2017-06-26", "last_synced_at": "2026-10-11T19:41:33.215Z", "location_count": 14, "location_summary": "Huntsville, Alabama • Colorado Springs, Colorado • Aventura, Florida + 10 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Aventura", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01768572" }, { "nct_id": "NCT07250815", "title": "A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ulcerative Colitis", "Crohn's Disease" ], "interventions": [ { "name": "No intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 23900, "start_date": "2026-09-21", "completion_date": "2026-12-15", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-11T19:41:33.215Z", "location_count": 1, "location_summary": "Cambridge, Massachusetts", "locations": [ { "city": "Cambridge", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07250815" }, { "nct_id": "NCT00298272", "title": "Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "IDEC-C2B8 (rituximab)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Folate", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 54, "start_date": "2006-05", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2015-09-28", "last_synced_at": "2026-10-11T19:41:33.215Z", "location_count": 18, "location_summary": "Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Palm Desert", "state": "California" }, { "city": "Jupiter", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00298272" }, { "nct_id": "NCT04772248", "title": "Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Tofacitinib", "type": "DRUG" }, { "name": "TNF Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105711, "start_date": "2021-02-22", "completion_date": "2021-12-30", "has_results": false, "last_update_posted_date": "2022-03-02", "last_synced_at": "2026-10-11T19:41:33.215Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04772248" }, { "nct_id": "NCT00932113", "title": "Mechanism of Action Study for Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Adalimumab (Humira)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tufts Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 33, "start_date": "2009-06", "completion_date": "2017-05-01", "has_results": true, "last_update_posted_date": "2017-08-31", "last_synced_at": "2026-10-11T19:41:33.215Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00932113" }, { "nct_id": "NCT00124982", "title": "Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" }, { "name": "Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)", "type": "DRUG" }, { "name": "Anti-Tumor Necrosing Factor (TNF) Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1286, "start_date": "2005-04", "completion_date": "2009-08", "has_results": true, "last_update_posted_date": "2012-02-27", "last_synced_at": "2026-10-11T19:41:33.215Z", "location_count": 114, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 111 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00124982" }, { "nct_id": "NCT07137598", "title": "A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Afimkibart", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2025-12-05", "completion_date": "2027-10-02", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-11T19:41:33.215Z", "location_count": 17, "location_summary": "Peoria, Arizona • La Jolla, California • Los Angeles, California + 13 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Tamarac", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07137598" }, { "nct_id": "NCT00796809", "title": "Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Coccidioidomycosis", "Rheumatoid Arthritis" ], "interventions": [], "intervention_types": [], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 598, "start_date": "2007-10", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2015-12-14", "last_synced_at": "2026-10-11T19:41:33.215Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00796809" }, { "nct_id": "NCT01721044", "title": "A Moderate to Severe Rheumatoid Arthritis Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "cDMARD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 527, "start_date": "2013-01", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2019-09-18", "last_synced_at": "2026-10-11T19:41:33.215Z", "location_count": 32, "location_summary": "Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 29 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Upland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01721044" } ] }